Table 4. Multivariate Analysis.

Factor	N	RR (95% CI)	P Value
NRM
Main effect
FDG-PET−	177	1
FDG-PET+	156	.754 (.479-1.185)	.2202
Donor type
HLA-identical sibling	120	1
Cord blood	53	2.691 (1.2-6.032)	.0162
Unrelated	160	3.595 (1.964-6.583)	<.0001
Stem cell source
Bone marrow	18	1
Peripheral blood	262	.33 (.16-.67)	.0025
Relapse/progression
Main effect
FDG-PET−	177	1
FDG-PET+	156	1.862 (1.263-2.745)	.0017
Histology
FL	104	1
DLBCL	82	2.365 (1.378-4.059)	.0018
MCL	69	2.122 (1.209-3.726)	.0088
T and NK neoplasm	78	1.882 (1.051-3.369)	.0333
Prior auto transplantation
Yes	66	1
No	267	.578 (.38-.881)	.0109
Therapy failure (PFS)
Main effect
FDG-PET−	177	1
FDG-PET+	156	1.297 (.966-1.741)	.0833
Donor type
HLA-identical sibling	120	1
Cord blood	53	1.896 (1.228-2.929)	.0039
Unrelated	160	1.521 (1.083-2.136)	.0155
Stem cell source
Bone marrow	18	1
Peripheral blood	262	.54 (.3-.5)	.03
Histology
FL	104	1
DLBCL	82	2.094 (1.401-3.131)	.0003
MCL	69	1.873 (1.23-2.853)	.0035
T and NK neoplasm	78	1.548 (.995-2.408)	.0527
Mortality (OS)
Main effect
FDG-PET−	177	1
FDG-PET+	159	1.321 (.946-1.844)	.1028
Donor type
HLA-identical sibling	122	1
Cord blood	53	2.098 (1.266-3.476)	.004
Unrelated	161	2.064 (1.379-3.09)	.0004
Stem cell source
Bone marrow	18	1
Peripheral blood	262	.38 (.21-.67)	.0008
Histology
FL	104	1
DLBCL	85	2.393 (1.489-3.846)	.0003
MCL	69	1.844 (1.118-3.041)	.0166
T and NK neoplasm	78	1.706 (1.01-2.883)	.0458
Conditioning regimen
Myeloablative	90	1
Non-myeloablative/RIC	246	.642 (0.447-0.921)	.0161